EM1042

EM1042 is a preclinical bispecific antibody candidate developed by EpimAb Biotherapeutics for the treatment of autoimmune diseases, specifically those involving inflammatory cells. Developed using EpimAb's proprietary FIT-Ig (Fabs-In-Tandem Immunoglobulin) platform, EM1042 functions as a T-cell engager (TCE). While the specific molecular targets are currently undisclosed by the developer, the therapeutic strategy involves leveraging T-cell engagement to modulate or deplete specific inflammatory cell populations responsible for autoimmune pathology. This approach represents an expansion of T-cell engager technology, which is traditionally used in oncology, into the field of immunology and inflammatory disorders.